Your browser doesn't support javascript.
loading
TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma.
Goyal, Lipika; Shi, Lei; Liu, Leah Y; Fece de la Cruz, Ferran; Lennerz, Jochen K; Raghavan, Srivatsan; Leschiner, Ignaty; Elagina, Liudmila; Siravegna, Giulia; Ng, Raymond W S; Vu, Phuong; Patra, Krushna C; Saha, Supriya K; Uppot, Raul N; Arellano, Ron; Reyes, Stephanie; Sagara, Takeshi; Otsuki, Sachie; Nadres, Brandon; Shahzade, Heather A; Dey-Guha, Ipsita; Fetter, Isobel J; Baiev, Islam; Van Seventer, Emily E; Murphy, Janet E; Ferrone, Cristina R; Tanabe, Kenneth K; Deshpande, Vikram; Harding, James J; Yaeger, Rona; Kelley, Robin K; Bardelli, Alberto; Iafrate, A John; Hahn, William C; Benes, Cyril H; Ting, David T; Hirai, Hiroshi; Getz, Gad; Juric, Dejan; Zhu, Andrew X; Corcoran, Ryan B; Bardeesy, Nabeel.
Affiliation
  • Goyal L; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Shi L; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Liu LY; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Fece de la Cruz F; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Lennerz JK; Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Raghavan S; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Leschiner I; Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
  • Elagina L; Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
  • Siravegna G; Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
  • Ng RWS; Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Torino, Italy.
  • Vu P; Department of Oncology, University of Torino, Candiolo, Torino, Italy.
  • Patra KC; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Saha SK; Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
  • Uppot RN; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Arellano R; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Reyes S; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Sagara T; Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Otsuki S; Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Nadres B; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Shahzade HA; Tsukuba Research Institute, Taiho Pharmaceutical Co., Ltd., Japan.
  • Dey-Guha I; Tsukuba Research Institute, Taiho Pharmaceutical Co., Ltd., Japan.
  • Fetter IJ; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Baiev I; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Van Seventer EE; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Murphy JE; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Ferrone CR; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Tanabe KK; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Deshpande V; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Harding JJ; Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Yaeger R; Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Kelley RK; Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Bardelli A; Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Iafrate AJ; Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Hahn WC; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California.
  • Benes CH; Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Torino, Italy.
  • Ting DT; Department of Oncology, University of Torino, Candiolo, Torino, Italy.
  • Hirai H; Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Getz G; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Juric D; Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
  • Zhu AX; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Corcoran RB; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Bardeesy N; Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Cancer Discov ; 9(8): 1064-1079, 2019 08.
Article in En | MEDLINE | ID: mdl-31109923
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Adenosine Triphosphate / Cholangiocarcinoma / Drug Resistance, Neoplasm / Protein Kinase Inhibitors / Receptor, Fibroblast Growth Factor, Type 2 Type of study: Diagnostic_studies / Prognostic_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Cancer Discov Year: 2019 Document type: Article Country of publication: Estados Unidos
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Adenosine Triphosphate / Cholangiocarcinoma / Drug Resistance, Neoplasm / Protein Kinase Inhibitors / Receptor, Fibroblast Growth Factor, Type 2 Type of study: Diagnostic_studies / Prognostic_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Cancer Discov Year: 2019 Document type: Article Country of publication: Estados Unidos